| Abstract: |
Background: Lipid lowering drugs are cornerstone in treatment of ischemic patient.However, the use of lipid lowering drugs is influenced by many factors e.g. financialstates and availability of many generic types. Statin treatment should be maintainedfor life in patient with acute coronary syndrome to prevent recurrence ofcardiovascular events. The pharmacological management of dyslipidemia has becomean important topic in lowering cardiovascular risk. Lipids are important biomolecules.For example, cholesterol is an essential component of the human cell membrane and aprecursor for steroid hormones and bile acids. Triglycerides also play an importantrole in transferring energy from food into body cells. However, any biomolecule inexcess is not good for human health. Similarly, elevation nof different forms of lipidsin the bloodstream, a condition generally termed hyperlipidemia, causes a constanthealth problem. Because lipids are carried in the bloodstream, hyperlipidemia isalways a threat to coronary arteries and the most important risk factor for coronaryheart disease. However, to fight these problems, human has acquired several drugs,commonly known as lipid-lowering drugs. One group of drugs (statins) lowerscholesterol by interfering with the cholesterol biosynthetic pathway. On the otherhand, fibrates decrease fatty acid and triglyceride levels by stimulating theperoxisomal p-oxidation pathway. A part from these drugs, ezetimibe, selectivelyinhibits intestinal cholesterol absorption.Objectives: The aim of the work was to evaluate the lipid profile and the use of lipidlowering drugs in patients with coronary artery disease in Zagazig UniversityHospitals.Patients and methods: This study was a cross-section and was carried out inDepartment of Cardiology, Zagazig University Hospitals on 200 patients with IHDeither chronic stable angina or unstable angina. The mean age of the patients takinglipid lowering therapy was 61.6 ± 6.8 and the mean age of the patients not taking lipidlowering therapy was 54.5 ± 7.5.Results: Our study showed that 37 patients had been treated with statins, 2 patientswith fibrates and only one patient had been treated with mixed treatment. Our studyshowed that 98 patients had not taken lipid lowering therapy because it is expensive,46 patients because this therapy was not prescribed, 9 patients due to negligence and 7, patients due to elevated liver enzymes from previous liver diseases. So, lipid lowerdrug has a positive effect on arteries especially coronal artery.Conclusion: only 20% of Egyptian patients who had acute coronary syndrome are onlipid-lowering therapy, mainly statins. Low socioeconomic status is the main causefor patient non-compliance followed by non-prescription, 4% of our patients hadelevated liver enzymes. 75% of patients on statin had diabetes mellitus compared tothose not on statin which is alarming and needs further assessment.
|
|
|